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In tissue engineering, the repair of critical-sized bone defects by using cells seeded onto biomaterial scaffolds remains a major challenge. It is well documented that the lack of vascularization within an engineered construct is the most important inhibiting factor for healing large bone defects. Proximity to a vascular network is necessary for survival of cells, adequate delivery of nutrients and oxygen, and removal of waste products. Consequently, cell death often occurs in the center of implants prior to vessel in-growth from the surrounding host tissue. Therefore, strategies that address the means of improving angiogenesis of bone tissue-engineered implants are vital. The present article is a commentary on the original research article by Pedersen and colleagues \[[@B1]\], which appeared in the previous issue of *Stem Cell Research* &*Therapy* and which is of utmost interest in this perspective. The authors created three-dimensional microvascular networks under dynamic culture conditions *in vitro* prior to implantation *in vivo*. The study consisted of fabricating porous copolymer scaffolds of poly(LLA-co-DXO) that were seeded either with human bone marrow-derived mesenchymal stem cells (hMSCs) alone or in unison with human umbilical vein endothelial cells (hUVECs). These three-dimensional constructs were maintained for 1 week *in vitro* prior to implantation subcutaneously in mice. Importantly, the authors showed that endothelial microvascular networks were observed after 1 week of *in vitro* culture and sustained after *in vivo* implantation within hUVEC/hMSC constructs*.* Moreover, incorporation of the implanted microvascular network with the host vasculature was observed after only 1 week of implantation *in vivo*\[[@B1]\].

The addition of hUVECs to mesenchymal stem cells (MSCs) influenced both angiogenic and osteogenic gene expression profiles \[[@B1]\]. However, the crosstalk molecules between these two types of cells as well as privileged molecular pathways toward gene expression remain unclear. Upregulated human vascular endothelial growth factor (VEGF) expression was observed in hUVEC/hMSC co-cultures compared with MSC monocultures after 3 weeks *in vivo*. Previous studies have shown that MSCs and osteoblasts produce VEGF and other paracrine signals that increase the survival and growth of endothelial cells \[[@B2],[@B3]\] and that mechanical loading of MSCs further enhances their paracrine pro-angiogenic properties \[[@B3]\]. Interestingly, Pedersen and colleagues \[[@B1]\] demonstrated that MSCs could support blood vessel formation *in vivo* by differentiating into perivascular cells, in agreement with previous findings \[[@B4]\]. Nevertheless, the perivascular transformation of MSCs was not enhanced by implanted hUVECs \[[@B1]\].

It has previously been shown that hUVECs enhanced the osteogenic differentiation of MSCs *in vitro*\[[@B5]-[@B7]\] and *in vivo*\[[@B5]\]. Grellier and colleagues \[[@B5]\] co-cultured hUVECs and hMSCs inside RGD (arginine-glycine-aspartic acid)-grafted alginate microspheres under dynamic conditions *in vitro* prior to implantation in a bone defect *in vivo*. Osteogenic gene expression, as well as mineralization *in vitro* and *in vivo*, was upregulated in co-cultures compared with monocultures of hMSCs \[[@B5]\]. Bidarra and colleagues \[[@B6]\] revealed that hUVECs, in addition to modulating the osteogenic differentiation of hMSCs, increase the proliferation rate of hMSCs. In another study, hUVECs enhanced the osteogenic differentiation of MSCs in a three-dimensional co-culture *in vitro* model through upregulation of bone morphogenetic expression \[[@B7]\]. Furthermore, the presence of hUVECs inhibited the adipogenic differentiation of MSCs by enhancing Wnt signaling \[[@B7]\]. Nevertheless, unlike in these previous studies, no difference in osteogenic gene expression, alkaline phosphatase, or alizarin red staining was observed in co-culture constructs compared with monoculture of hMSCs after *in vivo* implantation of three-dimensional constructs \[[@B1]\].

Most studies aiming to pre-vascularize implants for bone repair use hUVECs; however, these are macrovascular cells and therefore it would be interesting to assess the influence of microvascular cells, originating from capillaries, on MSC activity. Furthermore, it is known that macro- and micro-endothelial matrix components differ significantly and thus affect MSCs in different manners \[[@B8]\]. In this regard, Santos and colleagues \[[@B9]\] co-cultured human dermal microvascular endothelial cells with human osteoblasts (hOBs) in three dimensions. The authors achieved formation of a network of microcapillary-like structures, and hOB in co-culture significantly upregulated type I collagen and secreted higher amounts of VEGF compared with hOBs in monoculture \[[@B9]\]. A further microvascular cell type of interest would be pericyte cells. Indeed, in the setting of atherosclerosis, bone-like vascular calcifications co-localize with intraplaque angiogenesis, and microvascular pericytes are suspected to play a critical role in both mineralization and angiogenesis in atherosclerotic lesions \[[@B10]\].

Achieving the optimal culture conditions for pre-vascularized implants is imperative, and cell types, media components, cell densities, temporal variations in adding cells to co-culture, and dynamic loading are among the most important factors to consider. An important study by Correia and colleagues \[[@B11]\] demonstrated that, in tissue-engineered constructs, vasculogenesis should be induced prior to osteogenesis *in vitro* in order to obtain functional vasculature and osteoid formation following implantation *in vivo*.

For clinical applications of tissue engineering, vascular endothelial cells are inappropriate as they are not easily accessible and cannot be attained in sufficient quantities. Therefore, strategies to pre-vascularize implants by other means are under investigation. It has been shown that progenitor-derived endothelial cells enhance the differentiation of hMSCs to the same degree as hUVECs \[[@B12]\]; and Moioli and colleagues \[[@B13]\] have shown promising results for co-culture of hematopoietic and mesenchymal stem/progenitor cells in enhancing vascularization and osteoid formation in tissue-engineered constructs *in vivo*. The differentiation of MSCs into endothelial and pericyte-like cells has previously been shown in two-dimensional *in vitro* studies \[[@B14],[@B15]\]. However, landmark studies showed that MSCs alone are not entirely adequate for attaining fully vascularized implants \[[@B4],[@B16]\]. Duffy and colleagues \[[@B16]\] achieved capillary-like networks *in vitro* by using MSCs cultured with endothelial supplements within collagen-glycosaminoglycan scaffolds; however, vital endothelial cell markers were not present. Au and colleagues \[[@B4]\] demonstrated the need for both endothelial cells and MSCs to achieve functional blood vessels *in vivo*. A potential mechanism for pre-vascularized constructs, which encompasses many of the important features of the research articles highlighted in this commentary, is presented in Figure [1](#F1){ref-type="fig"}.

![**Schematic of possible mechanism of pre-vacularized implants for bone repair.** (**A**) Endothelial cells (red) and mesenchymal stem cells (MSCs) (yellow) are co-immobilized within a biomaterial scaffold (grey) *in vitro*. (**B**) Cells attach to the surface of biomaterial. Endothelial progenitor cells form a microvascular network, and some MSCs which have been exposed to endothelial growth supplements differentiate into perivascular cells (green). Other MSCs exposed to osteogenic supplement differentiate toward osteoblast cells. (**C**) After implantation *in vivo*, perivascular cells act to support blood vessels, the microvascular network fuses with host vasculature, osteoblasts line the surface of biomaterials, and new bone is formed with embedded osteocytes (black).](scrt307-1){#F1}

In conclusion, together these studies show that endothelial cells and MSCs enjoy a symbiotic relationship whereby they enhance osteogenic differentiation and angiogenesis, respectively. A crucial role of MSCs in attaining functional vascularized engineered scaffolds, as supporting cells to nascent blood vessels, has been demonstrated. Future work should explore the potential of three-dimensional pre-vascularized constructs by using more easily attainable, clinically relevant cell sources. Such a strategy, which may achieve rapid anastomosis *in vivo* and thereby greatly enhance bone repair and carry the possibility of patient-specific constructs, would be of the utmost interest to the bone tissue-engineering field.
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